Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioAdvance Capital is an evergreen venture capital fund established to support early-stage life-science companies dedicated to improving human health. Founded in Conshohocken, Pennsylvania, the firm primarily invests in companies located along the I-95 corridor between New York City and Washington, D.C. This geographic focus allows BioAdvance to tap into a vibrant network of life science innovation in the Mid-Atlantic region.
The organization has a strong commitment to fueling innovation in the life sciences sector by providing crucial early-stage funding and strategic support to entrepreneurs. BioAdvance Capital has invested in over 120 companies, collectively attracting more than $4.4 billion in follow-on funding. The firm is led by a team of experienced professionals, including Managing Director & CEO Shahram Hejazi, Ph.D., and partners Gregory Harriman, M.D., and David Shin, M.D.
BioAdvance Capital focuses on early-stage life-science companies, particularly in sectors such as Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. The firm primarily targets seed and Series A investment opportunities, providing funding that enables companies to reach critical milestones. This approach enhances their appeal to larger venture capital firms and other funding sources.
The typical investment size ranges from $500,000 to $1.5 million, with the potential to commit up to $5 million over the lifecycle of a company. BioAdvance Capital seeks to partner with entrepreneurs who are dedicated to advancing human health through innovative life science solutions. The firm’s investment strategy emphasizes not only financial support but also strategic guidance to help portfolio companies navigate the complexities of the healthcare market.
BioAdvance Capital has built a diverse portfolio of over 120 companies, showcasing its commitment to the life sciences sector. Notable portfolio companies include:
These companies have collectively attracted over $4.4 billion in follow-on funding, demonstrating the effectiveness of BioAdvance Capital's investment strategy.
Shahram Hejazi, Ph.D. - Managing Director & CEO. Hejazi has extensive experience in the life sciences sector and has led numerous successful investments in early-stage companies.
Gregory Harriman, M.D. - Partner. Harriman brings a medical background and expertise in therapeutics, contributing to the firm's investment strategy.
David Shin, M.D. - Partner. Shin has a strong background in healthcare investments and plays a key role in evaluating potential portfolio companies.
To pitch to BioAdvance Capital, founders should use the contact form available on their website at BioAdvance Contact. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. The firm typically reviews submissions and responds within a few weeks. Warm introductions are preferred but not mandatory.
In recent months, BioAdvance Capital has been active in the life sciences sector, publishing blog posts that highlight significant collaborations and advancements. Topics covered include strategic partnerships in cell therapy and the application of AI in healthcare. The firm has also discussed acquisitions that enhance health technology platforms, showcasing its engagement with current industry trends.
BioAdvance Capital continues to demonstrate its commitment to supporting early-stage life science companies through regular updates and insights shared on its platform.
What are BioAdvance Capital's investment criteria?
BioAdvance Capital invests in early-stage life science companies, particularly those in the Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools sectors. The firm primarily targets seed and Series A funding opportunities.
How can I apply or pitch to BioAdvance Capital?
Founders can pitch to BioAdvance Capital through their website at BioAdvance Contact. It is recommended to provide a detailed business plan and financial projections in the pitch deck.
What makes BioAdvance Capital different from other venture capital firms?
BioAdvance Capital focuses specifically on early-stage life science companies and offers not only funding but also strategic support to help entrepreneurs navigate the healthcare landscape. Their geographic focus on the Mid-Atlantic region allows them to leverage local networks and resources.
What is the geographic scope of BioAdvance Capital's investments?
The firm primarily invests in companies located along the I-95 corridor between New York City and Washington, D.C., targeting the Mid-Atlantic region of the United States.
What is the typical check size for investments?
BioAdvance Capital typically invests between $500,000 and $1.5 million in early-stage companies, with the potential to commit up to $5 million over the lifecycle of a company.
What kind of post-investment involvement does BioAdvance Capital have?
BioAdvance Capital provides strategic support and guidance to its portfolio companies, helping them achieve critical milestones and enhance their attractiveness to larger venture capital firms.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.